Proactive Investors - Run By Investors For Investors

Oventus Medical launches lightweight sleep apnoea treatment device in Australia

The Optima device is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and improves the effectiveness of oral appliance therapy.
Oventus Medical launches lightweight sleep apnoea treatment device in Australia
The O2Vent Optima device

Oventus Medical Ltd (ASX:OVN) has launched its nylon-made O2Vent Optima device for the treatment of sleep apnoea in Australia.

The compact device is a lightweight addition to the Oventus sleep treatment platform and has reduced cost of goods in comparison to the original titanium-made O2Vent.

Optima incorporates Brisbane-based Oventus’ proprietary airway technology and is compatible with the Oventus ExVent valve technology which will also be launched this year.

“Discrete and flexible alternative”

Oventus managing director & CEO Chris Hart said: “We are excited to be launching the O2Vent Optima as the next generation O2Vent product addition to our sleep treatment platform.

“This lightweight, durable device incorporating Oventus airway technology offers a more discrete and flexible alternative to those that cannot tolerate continuous positive airway pressure (CPAP) therapy.”

The Optima device is lighter than the original O2Vent and less complex to make.

The combination of reduced material costs and lower manufacturing time brings down costs and will shorten timeframes for delivery to patients.

Dramatically improves treatment outcomes

Clinical trials have shown that Oventus’ proprietary airway, both unitarily and in combination with the ExVent technology, dramatically improves treatment outcomes for sufferers of obstructive sleep apnoea.

ExVent was developed in collaboration with CSIRO and Neuroscience Research Australia during a three-year, $2.95-million federally-funded Cooperative Research Centre project grant.

ExVent is due to be released this quarter and following both the Optima and ExVent launches in Australia, the products will also be released in North American and European markets.

Patented airway technology

Oventus is a medical device company commercialising a unique treatment platform for the treatment of sleep apnoea and snoring.

Unlike other oral appliances or CPAP interfaces, the Oventus devices have a patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position.

This airway bypasses multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintaining a stable airway with or without nasal CPAP.

The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present then breathing is supplemented through the airways in the device.

View full OVN profile View Profile

Oventus Medical Ltd Timeline

Related Articles

Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use